Celltrion Inc represents values of innovation, growth, and commitment. The company's corporate philosophy revolves around advancing healthcare through the development of biopharmaceuticals and biosimilars. With a focus on research and development, Celltrion Inc aims to provide effective and affordable treatment options for patients worldwide. By harnessing cutting-edge technology and fostering collaboration, the company strives to make significant contributions to the field of biotechnology. Celltrion Inc's commitment to delivering high-quality products and improving global healthcare standards makes it a prominent player in the pharmaceutical industry.

Celltrion Inc is primarily present in South Korea.

Celltrion Inc has achieved several significant milestones. One notable achievement is the approval and successful launch of their biosimilar drugs, such as Inflectra and Remsima, which have had a positive impact on the healthcare industry. Additionally, Celltrion Inc has made advancements in research and development, particularly in the field of monoclonal antibodies for diseases like cancer and autoimmune disorders. The company has also expanded its global reach by securing strategic partnerships and collaborations with other pharmaceutical companies. These milestones demonstrate Celltrion Inc's commitment to innovation and its ability to produce high-quality biopharmaceutical products.

Celltrion Inc, a renowned biopharmaceutical company based in South Korea, was founded in 2002. With a strong focus on innovation and research, Celltrion has emerged as a global leader in developing and producing biosimilar and innovative biopharmaceuticals. The company has a diverse portfolio of products, including treatments for autoimmune diseases, cancer, and infectious diseases. Celltrion's commitment towards delivering high-quality therapeutics at an affordable cost has garnered international recognition. By leveraging its expertise in biotechnology, Celltrion continues to strive towards improving healthcare standards and ensuring patient well-being. With a successful track record and a dedication to advancing medical advancements, Celltrion Inc has established itself as a prominent player in the pharmaceutical industry.

The main competitors of Celltrion Inc in the market include leading biopharmaceutical companies such as Samsung Bioepis, Pfizer Inc., Amgen Inc., and Roche Holding AG. These companies are actively engaged in the development and commercialization of innovative biologic medicines, which may compete with Celltrion's biosimilar products in various therapeutic areas. Celltrion, however, has established a strong market presence and competitive advantage through its expertise in biosimilars manufacturing, research and development capabilities, and strategic partnerships.

Celltrion Inc is primarily active in the biopharmaceutical industry.

Celltrion Inc's business model focuses on the development, manufacturing, and sales of biopharmaceutical products. As a global biotechnology company, Celltrion specializes in the production of biosimilars, which are highly similar versions of existing biological medicines. By utilizing advanced technology and innovative research, Celltrion aims to provide affordable and accessible treatments to patients worldwide. The company's key strategies involve extensive research and development efforts to expand its product portfolio, strategic collaborations with international partners, and a commitment to enhancing healthcare accessibility. Through its business model, Celltrion Inc strives to contribute to the advancement of the pharmaceutical industry and positively impact patient lives.

P/E odnos Celltrion iznosi 48,10.

KUV kompanije Celltrion iznosi 7,62.

AlleAktien kvalitativni skor za Celltrion je 7/10.

očekivana Celltrion promet je 3,48 Bio. KRW.

Dobit očekivana Celltrion je 551,33 milijardi KRW.

Celltrion Inc. is a Korean biotechnology company that specializes in the research, development, and manufacturing of biological drugs. The company was founded in 2002 and is headquartered in Incheon, South Korea. Celltrion Inc. is involved in various business areas, including the development of biosimilars, distribution of biologics, and development of antibiotics.

Celltrion isplaćuje dividendu od 360,58 KRW raspoređenu preko 1 isplata u toku godine.

Celltrion isplaćuje dividendu 1 puta godišnje.

ISIN od Celltrion je KR7068270008.

WKN od Celltrion je A0RM6K.

Oznaka za praćenje akcija kompanije Celltrion je 068270.KS.

U poslednjih 12 meseci, Celltrion je isplatio dividendu u iznosu od 500,00 KRW . To odgovara dividendnom prinosu od oko 0,27 %. Za narednih 12 meseci, Celltrion će verovatno isplatiti dividendu od 557,25 KRW.

Dividendski prinos od Celltrion trenutno iznosi 0,27 %.

Celltrion isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima јануар, јануар, јануар, јануар.

Celltrion je isplaćivao dividendu svake godine u poslednjih 6 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 557,25 KRW. To odgovara dividendnom prinosu od 0,30 %.

Celltrion se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Celltrion od 1. 3. 2024. u iznosu od 500 KRW, morali ste da imate akciju u depou pre Ex-dana 27. 12. 2023..

Isplata poslednje dividende izvršena je 1. 3. 2024..

U godini 2023 kompanija Celltrion je isplatila 360,577 KRW kao dividende.

Dividende od Celltrion se isplaćuju u KRW.